Currently, several emerging drugs, such as CDK4/6 inhibitors (Wu et al., 2020) and poly (ADP-ribose) polymerase (PARP) inhibitors (Rose et al., 2020), have gradually become the first-line treatment for BC; however, few models have been developed for predicting the efficacy of these drugs. The gene discussed is PARP1; the disease is breast cancer.